Domenico Ribatti
University of Bari
965 Papers
6.1K Citations
Domenico Ribatti is an academic researcher from University of Bari. The author has contributed to research in topics: Angiogenesis & Biology. The author has an hindex of 96, co-authored 913 publications. Previous affiliations of Domenico Ribatti include University of Genoa & National Institutes of Health.
Chat about Author
Papers
Neovascularization is prominent in the chronic inflammatory lesions of Sjögren's syndrome.
Margherita Sisto,Sabrina Lisi,Giuseppe Ingravallo,Dario Domenico Lofrumento,Massimo D'Amore,Domenico Ribatti +5 more
TL;DR: Findings reveal that angiogenesis is intimately involved in the progression of Sjögren's syndrome, may be central to the propagation of the chronic immune response observed in pSS and could represent a novel potential biomarker of pSS disease activity.
A novel ex vivo murine retina angiogenesis (EMRA) assay
Sara Rezzola,Mirella Belleri,Domenico Ribatti,Ciro Costagliola,Marco Presta,Francesco Semeraro +5 more
TL;DR: The EMRA assay represents a new ex vivo model of retinal neovascularization suitable for the rapid screening of novel anti-angiogenic therapeutics and demonstrates that both antibodies inhibit VEGF activity in a dose-dependent manner.
A revisited concept: Contact inhibition of growth. From cell biology to malignancy
TL;DR: Not only the movement but also the proliferation of many normal cells is inhibited by cell-cell contact, and cancer cells are characteristically insensitive to such contact inhibition.
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer.
TL;DR: In this paper, the association of multiple anti-angiogenic molecules or a combination of anti-ngiogenic drugs with other treatment regimens have been indicated as alternative therapeutic strategies to overcome resistance to anti-vascular endothelial growth factor (VEGF) molecules.
TGFβ1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjögren's syndrome.
TL;DR: This study demonstrates the IL-17-dependent activation of EMT in human SG epithelial cells that occurs through both the canonical TGF-β1/Smad2/3 and noncanonical TGF1/Erk1/2 pathways.